Physician profile
Mukesh Gupta
NPI 1679567655
$407.41
in general payments reported to CMS, 2019-2025
11 companies · $206 in 2025
The $206 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.39 · 2022: $106 · 2023: $47.73 · 2024: $33.21 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $286.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $81.96 | 2024-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $65.77 | 2025 | Rotapro, Bodyguardian, Cds - Mct/Cem Monitoring |
| Penumbra, INC. | $64.91 | 2022 | |
| Abiomed | $41.25 | 2022 | |
| Amgen INC. | $33.30 | 2023-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $29.57 | 2020-2023 | Xarelto |
| Alnylam Pharmaceuticals INC. | $22.18 | 2025 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.81 | 2025 | Jardiance |
| Esperion Therapeutics, INC. | $16.22 | 2023 | Nexletol |
| Bridgebio Pharma, INC. | $15.96 | 2025 | Attruby |
| Inspire Medical Systems, INC. | $14.48 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukesh Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.